Ventus Medical announces the publication of clinical trial data for its new Theravent Advanced Nightly Snore Therapy in Sleep Diagnosis and Therapy, a medical journal for sleep professionals .
The randomized, controlled trial of 49 patients demonstrated that successful users of Theravent averaged a 76% reduction in snoring as assessed using a decibel meter. Additionally, bed partners in the study reported a statistically significant reduction in snoring duration and volume. The study also found that the level of snoring reduction with Theravent was on average about five times that of nasal strips. Theravent is available to consumers online at www.theraventsnoring.com  (no prescription required).
"The results of this rigorous study demonstrate very significant improvements in snoring. As a sleep physician, I am delighted and relieved that there is finally a practical snoring treatment that truly works. Theravent should be a welcome option for 45 million snorers in the US and their bed partners who suffer from the effects of snoring," said Philip Westbrook, MD, co-author of the study and Chief Medical Officer of Ventus Medical. "Theravent represents an important, clinically proven option for healthcare providers to recommend to their patients who snore."
Theravent is for people whose snoring affects sleep quality for themselves or their bed partner. Theravent is FDA-cleared and indicated to reduce or eliminate snoring. Theravent uses similar MicroValve Technology first introduced in Ventus Medical's prescription-only Provent Sleep Apnea Therapy. MicroValve Technology has now been proven in more than 15 clinical trials and used for nearly two million nights of sleep. This revolutionary technology increases pressure in the upper airway when a user exhales, creating expiratory positive airway pressure (EPAP), which keeps the airway open and reduces snoring.
About Theravent Advanced Nightly Snore Therapy
Theravent is a new, clinically proven, over-the-counter treatment for snoring. Theravent offers a proven solution for patients whose snoring is affecting the quality of their and their partners' sleep. Used nightly, Theravent gives snorers and their partners a quiet night's sleep. Theravent uses patented MicroValve Technology, previously only available with a prescription, to target and treat snoring. During inhalation, the MicroValves open--allowing nearly unobstructed airflow. During exhalation, the MicroValves partially close, which increases expiratory pressure and keeps the airway open, preventing snoring. Theravent received FDA clearance in June of 2012. Theravent is not intended to treat obstructive sleep apnea.
About Provent Sleep Apnea Therapy
Provent Sleep Apnea Therapy is a proprietary medical device for the treatment of obstructive sleep apnea (OSA). The device has proven to be clinically effective in a series of published studies. It is an easy to use, non-invasive disposable treatment that works across mild, moderate and severe OSA. Provent Sleep Apnea Therapy utilizes nasal expiratory positive airway pressure (EPAP) to keep a patient's airway open during sleep. It incorporates a novel MicroValve design that is placed over the nostrils and secured with hypoallergenic adhesive. During inhalation, the valve opens allowing nearly unobstructed airflow. During exhalation, the valve closes, limiting airflow through small openings, which increases expiratory pressure and keeps the airway open, preventing disruption in breathing. Provent Sleep Apnea Therapy is FDA cleared, has CE marking and has been accepted onto the Australian Register of Therapeutic Goods (ARTG).
Source: Ventus Medical  via PR Newswire